164 related articles for article (PubMed ID: 26823519)
1. PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.
Pharoah PDP; Song H; Dicks E; Intermaggio MP; Harrington P; Baynes C; Alsop K; ; Bogdanova N; Cicek MS; Cunningham JM; Fridley BL; Gentry-Maharaj A; Hillemanns P; Lele S; Lester J; McGuire V; Moysich KB; Poblete S; Sieh W; Sucheston-Campbell L; Widschwendter M; ; Whittemore AS; Dörk T; Menon U; Odunsi K; Goode EL; Karlan BY; Bowtell DD; Gayther SA; Ramus SJ
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26823519
[TBL] [Abstract][Full Text] [Related]
2. Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
Swisher EM; Harrell MI; Norquist BM; Walsh T; Brady M; Lee M; Hershberg R; Kalli KR; Lankes H; Konnick EQ; Pritchard CC; Monk BJ; Chan JK; Burger R; Kaufmann SH; Birrer MJ
JAMA Oncol; 2016 Mar; 2(3):370-2. PubMed ID: 26847329
[TBL] [Abstract][Full Text] [Related]
3. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.
Ruark E; Snape K; Humburg P; Loveday C; Bajrami I; Brough R; Rodrigues DN; Renwick A; Seal S; Ramsay E; Duarte Sdel V; Rivas MA; Warren-Perry M; Zachariou A; Campion-Flora A; Hanks S; Murray A; Ansari Pour N; Douglas J; Gregory L; Rimmer A; Walker NM; Yang TP; Adlard JW; Barwell J; Berg J; Brady AF; Brewer C; Brice G; Chapman C; Cook J; Davidson R; Donaldson A; Douglas F; Eccles D; Evans DG; Greenhalgh L; Henderson A; Izatt L; Kumar A; Lalloo F; Miedzybrodzka Z; Morrison PJ; Paterson J; Porteous M; Rogers MT; Shanley S; Walker L; Gore M; Houlston R; Brown MA; Caufield MJ; Deloukas P; McCarthy MI; Todd JA; ; ; Turnbull C; Reis-Filho JS; Ashworth A; Antoniou AC; Lord CJ; Donnelly P; Rahman N
Nature; 2013 Jan; 493(7432):406-10. PubMed ID: 23242139
[TBL] [Abstract][Full Text] [Related]
4. Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.
Kim B; Won D; Lee ST; Choi JR
PLoS One; 2019; 14(6):e0217521. PubMed ID: 31242196
[TBL] [Abstract][Full Text] [Related]
5. PPM1D mutations in circulating white blood cells and the risk for ovarian cancer.
Akbari MR; Lepage P; Rosen B; McLaughlin J; Risch H; Minden M; Narod SA
J Natl Cancer Inst; 2014 Jan; 106(1):djt323. PubMed ID: 24262437
[TBL] [Abstract][Full Text] [Related]
6. Detectible mosaic truncating PPM1D mutations, age and breast cancer risk.
Machiela MJ; Myers TA; Lyons CJ; Koster R; Figg WD; Colli LM; Jessop L; Ahearn TU; Freedman ND; García-Closas M; Chanock SJ
J Hum Genet; 2019 Jun; 64(6):545-550. PubMed ID: 30850729
[TBL] [Abstract][Full Text] [Related]
7. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
Zajkowicz A; Butkiewicz D; Drosik A; Giglok M; Suwiński R; Rusin M
Br J Cancer; 2015 Mar; 112(6):1114-20. PubMed ID: 25742468
[TBL] [Abstract][Full Text] [Related]
8. Truncating and missense PPM1D mutations in early-onset and/or familial/hereditary prostate cancer patients.
Cardoso M; Paulo P; Maia S; Teixeira MR
Genes Chromosomes Cancer; 2016 Dec; 55(12):954-961. PubMed ID: 27401275
[TBL] [Abstract][Full Text] [Related]
9. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.
Zhang L; Chen LH; Wan H; Yang R; Wang Z; Feng J; Yang S; Jones S; Wang S; Zhou W; Zhu H; Killela PJ; Zhang J; Wu Z; Li G; Hao S; Wang Y; Webb JB; Friedman HS; Friedman AH; McLendon RE; He Y; Reitman ZJ; Bigner DD; Yan H
Nat Genet; 2014 Jul; 46(7):726-30. PubMed ID: 24880341
[TBL] [Abstract][Full Text] [Related]
10. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
Tan DS; Lambros MB; Rayter S; Natrajan R; Vatcheva R; Gao Q; Marchiò C; Geyer FC; Savage K; Parry S; Fenwick K; Tamber N; Mackay A; Dexter T; Jameson C; McCluggage WG; Williams A; Graham A; Faratian D; El-Bahrawy M; Paige AJ; Gabra H; Gore ME; Zvelebil M; Lord CJ; Kaye SB; Ashworth A; Reis-Filho JS
Clin Cancer Res; 2009 Apr; 15(7):2269-80. PubMed ID: 19293255
[TBL] [Abstract][Full Text] [Related]
11. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
Ramus SJ; Song H; Dicks E; Tyrer JP; Rosenthal AN; Intermaggio MP; Fraser L; Gentry-Maharaj A; Hayward J; Philpott S; Anderson C; Edlund CK; Conti D; Harrington P; Barrowdale D; Bowtell DD; Alsop K; Mitchell G; ; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Sieh W; McGuire V; Lester J; Bogdanova N; Dürst M; Hillemanns P; ; Odunsi K; Whittemore AS; Karlan BY; Dörk T; Goode EL; Menon U; Jacobs IJ; Antoniou AC; Pharoah PD; Gayther SA
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26315354
[TBL] [Abstract][Full Text] [Related]
12. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
13. Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem MM; AlGhamdi B; Moria Y; Al-Hindi H
Endocrine; 2019 Jan; 63(1):94-100. PubMed ID: 30269267
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
[TBL] [Abstract][Full Text] [Related]
15. Genetic variants and mutations of PPM1D control the response to DNA damage.
Dudgeon C; Shreeram S; Tanoue K; Mazur SJ; Sayadi A; Robinson RC; Appella E; Bulavin DV
Cell Cycle; 2013 Aug; 12(16):2656-64. PubMed ID: 23907125
[TBL] [Abstract][Full Text] [Related]
16. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
17. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
Kleiblova P; Shaltiel IA; Benada J; Ševčík J; Pecháčková S; Pohlreich P; Voest EE; Dundr P; Bartek J; Kleibl Z; Medema RH; Macurek L
J Cell Biol; 2013 May; 201(4):511-21. PubMed ID: 23649806
[TBL] [Abstract][Full Text] [Related]
18. Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues.
Kim ET; Jeong HE; Yoon HJ; Kim KH; Suh DS
Taiwan J Obstet Gynecol; 2023 Jan; 62(1):66-70. PubMed ID: 36720553
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
[TBL] [Abstract][Full Text] [Related]
20. Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer.
Weber-Lassalle K; Ernst C; Reuss A; Möllenhoff K; Baumann K; Jackisch C; Hauke J; Dietrich D; Borde J; Park-Simon TW; Hanker L; Prieske K; Schmidt S; Weber-Lassalle N; Pohl-Rescigno E; Kommoss S; Marmé F; Heitz F; Stingl JC; Schmutzler RK; Harter P; Hahnen E
J Natl Cancer Inst; 2022 Apr; 114(4):565-570. PubMed ID: 34963005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
